English Nederlands MENU NEWS 7 Oct 2021 NLO advises Precirix in major trial milestone PATENTS Caroline Pallard and her team have been assisting Belgian biotech company Precirix. Precirix develops precision radiopharmaceuticals in oncology. On 6 October the company announced a major milestone of its lead therapeutic asset; it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for the treatment of HER2-positive metastatic cancer. Worldwide, >1.6 m cases of breast cancer and >1.2m cases of gastric cancer are diagnosed annually, of which >20% are HER2-positive. At this moment, there are no approved HER2 targeting radiopharmaceuticals and CAM-H2 is the lead candidate in therapeutic development. About Precirix Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment. Read more: Precirix dosed first patients in Phase I/II clinical study | Precirix Image: Precirix.com Our experts Caroline Pallard Dutch and European patent attorney Dietmar Hertsen Dutch patent attorney Share this page Offices in Amsterdam The Hague Ede Eindhoven Ghent Mechelen Follow us Contact P.O. Box 29720 2502 LS The Hague Contact us Newsletter Stay informed and subscribe to our newsletter. Subscribe Terms and Conditions Disclaimer and Privacy Legal Media